Firms invested CHF16.8 billion ($18 billion) in research and development (R&D) activities in Switzerland last year, a 4% increase compared to 2019.
This content was published on
2 minutes
FSO/Keystone-SDA/sb
A survey carried out by the Federal Statistical Office (FSO) and the Swiss Business Federation economiesuisse said the pharmaceutical sector was the biggest R&D investor (CHF6.2 billion, or 37% of the total).
The overall CHF1.3 billion rise since 2019 was in line with a recent upward trend, but it is all the more remarkable given the difficult economic situations in 2020 and 2021 caused by the Covid-19 pandemic, the FSO said in a statementExternal link on Monday.
Fundamental research fell from around one quarter of companies’ overall research investment in 2015 to 8% in 2021. This is mainly due to changes in the type of research carried out within pharmaceutical companies, the FSO said.
More
More
The end of affordable medicine
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
Looking at the different specialist fields, R&D investment in biotechnology has steadily increased since 2012, the statistics office said. In 2021, companies invested CHF5.9 billion in this area, or 35% of total R&D spending.
Firms invested CHF6.3 billion on R&D abroad – a slight decrease – the FSO said.
“After strong growth between 2012 and 2017, the current trend seems to show that companies are finding in Switzerland the means to meet their own R&D needs,” it said.
Last year, companies employed nearly 62,000 people working on R&D, an annual increase of 2% since 2019. A quarter of all research staff were women, a percentage that has remained the same over the past ten years.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
Swiss authorities announce cost-cutting in asylum sector
This content was published on
The government notably wants to improve integration into the labour force, particularly for people with protection status S.
Various leaders confirm participation at Ukraine peace conference
This content was published on
The presidents of Poland, Finland, and Latvia and the prime ministers of Spain and Belgium will be at the Swiss-hosted talks in mid-June.
This content was published on
In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.
Rhine flooding: Swiss to invest CHF1 billion with Austria
This content was published on
As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.
Swiss government proposes CHF10 million UNRWA donation
This content was published on
After months of debate, Switzerland plans to give CHF10 million ($11 million) to the UN agency this year, rather than the CHF20 million initially foreseen.
Swiss study: insects mainly migrate at midday and dusk
This content was published on
A study led by the Swiss Ornithological Institute in canton Lucerne is helping to better understand the movement patterns of migratory insects.
Red Cross: 22 staff killed in Middle East since October
This content was published on
The Red Cross and Red Crescent network in Gaza and Israel has lost 22 staff members since last October, the Swiss Red Cross (SRC) said on Wednesday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland and UK sign major agreement on science and innovation
This content was published on
The agreement, signed by the UK and Switzerland, is to deepen ties between their respective research and innovation communities.
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.